Telefon:: +49 (0)241 95 163 153
Fax:: +49 (0)241 95 163 155
E-Mail:: orders@antikoerper-online.de

Aktivieren Sie Javascript in Ihrem Browser, um unsere Webseite optimal zu nutzen.

SET Nuclear Oncogene (SET) Peptid

SET Reaktivität: Human Wirt: Kaninchen BP

Produktnummer ABIN2764137

Datenblatt (PDF)

Kurzübersicht für SET Nuclear Oncogene (SET) Peptid (ABIN2764137)

Target

SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Spezies

Human

Quelle

Kaninchen

Applikation

Blocking Peptide (BP)

SET Nuclear Oncogene (SET) peptide
SET Reaktivität: Säugetier Wirt: Synthetic BP, IHC, WB

SET Nuclear Oncogene (SET) peptide
SET Reaktivität: Human, Rind (Kuh) Wirt: Synthetic BP, Imm

SET Nuclear Oncogene (SET) (N-Term) peptide
SET Reaktivität: Human Wirt: Synthetic BP, IHC, WB, IP

SET Nuclear Oncogene (SET) peptide
SET Reaktivität: Human Wirt: Synthetic BP, BI

Beschränkungen

Nur für Forschungszwecke einsetzbar
Lagerung

-20 °C
Target

SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Hintergrund

Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.

Sie sind hier: